Sarepta touts Duchenne gene therapy uptake, but warns of demand flattening before potential expanded label from FDA

Sarep­ta Ther­a­peu­tics an­nounced Wednes­day af­ter­noon that its Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py Ele­v­idys pulled in $200 mil­lion in its first half-year on the com­mer­cial mar­ket.

In the fourth quar­ter of 2023, the gene ther­a­py’s sales jumped to $131.2 mil­lion, up from $69 mil­lion in the first few months it was on the mar­ket. All in all, the biotech eclipsed $1 bil­lion in sales in 2023 on all its Duchenne med­i­cines, which in­clude three “ex­on-skip­ping” drugs in ad­di­tion to the gene ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.